The secreted aspartic proteinases as a new target in the therapy of candidiasis.

Abstract

Secreted aspartic proteinases (Saps) are important virulence factors in different types of candidiasis caused by Candida albicans (C. albicans). The various isoenzymes are expected to fulfil different tasks during mucosal or disseminated infections. It could be shown that the introduction of the proteinase inhibitors like saquinavir and indinavir in the therapy of human immunodeficiency virus (HIV) infected patients has an effect on Sap activity in vitro as well as in vivo. Therefore, drugs like the HIV proteinase inhibitors could play an essential role in the treatment of candidiasis in the future, especially if further adapted to this target.

• Authors: M Bein, M Schaller, H C Korting
• Journal: Current drug targets (Curr Drug Targets) Vol. 3 Issue 5 Pg. 351-7 (Oct 2002) ISSN: 1389-4501 [Print] United Arab Emirates
• PMID: 12182226 (Publication Type: Journal Article, Review)

Chemical References

• HIV Protease Inhibitors
• Isoenzymes
• Protease Inhibitors
• Aspartic Acid Endopeptidases

Topics

• Aspartic Acid Endopeptidases (antagonists & inhibitors, chemistry, metabolism)
• Candida albicans (drug effects, enzymology)
• Candidiasis (drug therapy)
• Drug Delivery Systems
• Epithelium (drug effects, microbiology)
• Extracellular Space (enzymology)
• HIV Protease Inhibitors (therapeutic use)
• Humans
• Isoenzymes (antagonists & inhibitors, chemistry, metabolism)
• Protease Inhibitors (pharmacology, therapeutic use)
• Virulence